|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Between 2010 and 2016, 304 adult patients with de novo MDS had the FLT3 sequence tested on their bone marrow sample.
|
30555035 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite the MDS cohort being older, they had significantly longer telomeres than the AML cohort (P < 0·0001) where telomere length was also significantly shorter in younger AML patients (age <60 years) (P = 0·02) and in FLT3 internal tandem duplication-mutated AML patients (P = 0·03).
|
28486748 |
2017 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Three high-risk MDS cases (1.2%) displayed chromothripsis involving exclusively chromosome 13 and affecting some cancer genes: FLT3, BRCA2 and RB1.
|
27741277 |
2016 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We analyzed 102 MDS patients who were admitted to our institution between 2004 and 2013, had wild-type (wt) FLT3-ITD and RAS at diagnosis, progressed to AML, and had serial mutation testing at both the MDS and AML stages.
|
26547258 |
2015 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The t(6;9)/DEK-NUP214 was associated with relatively late onset (median age 10.4 years), male predominance (sex ratio 1.7), French-American-British M2 classification (54%), myelodysplasia (100%), and FLT3-ITD (42%).
|
24441146 |
2014 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Recent studies are shedding light on the molecular basis of myelodysplasia and how mutations and epimutations can induce and promote this neoplastic process through aberrant transcription factor function (RUNX1, ETV6, TP53), kinase signalling (FLT3, NRAS, KIT, CBL) and epigenetic deregulation (TET2, IDH1/2, DNMT3A, EZH2, ASXL1, SF3B1, U2AF1, SRSF2, ZRSR2).
|
24903747 |
2014 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Median overall survival (OS) for FLT3-mutated MDS patients was 19.0 months versus 16.4 months for FLT3-nonmutated MDS patients (P = 0.08).
|
23115106 |
2013 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We therefore combined the FLT3/ITD mutation with a model of myelodysplastic syndrome involving transgenic expression of the Nup98-HoxD13 (NHD13) fusion gene.
|
22323452 |
2012 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MK(+) patients were significantly older (P = .0001), had lower white blood counts (P = .0006), and lower percentages of BM blasts (P = .0004); MK was associated with the presence of -5/5q-, -7, 7q-, abnl(12p), abnl(17p), -18/18q-, -20/20q-, inv(3)/t(3;3), complex karyotype (CK), and myelodysplasia (MDS)-related cytogenetic abnormalities (P < .0001, each); and NPM1 mutations (P < .0001), FLT3 internal tandem duplications (P < .0001), and tyrosine kinase domain mutations (P = .02) were less frequent in MK(+).
|
22096250 |
2012 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The frequencies of FLT3 and NPM1 mutation were 2.0% and 4.4%, respectively, and mutations were restricted to cases of intermediate- and high-risk MDS.
|
21173125 |
2011 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Additional molecular mutations were found in 23/43 NPM1mut s-AML after MDS (53.5%) and in transformed MPN in 18/37 (48.6%): FLT3-ITD: 14/37 (37.8%); FLT3-TKD: 3/28 (10.7%); NRASmut: 4/37 (10.8%), RUNX1mut: 1/16 (6.3%).
|
21233837 |
2011 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Development and progression of MDS to acute myeloid leukemia is suggested to be a multistep alteration to hematopoietic stem cells consisting of class I and class II alterations: the former targeting genes that are involved in signal transduction (e.g., FLT3, RAS and KIT), whereas the latter affect transcription factors (e.g., RUNX, RARA, EVI1 and WT1).
|
20222800 |
2010 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
|
19279329 |
2009 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariate analysis showed the effects of leukocytosis (p = 0.0013), antecedent Myelodysplastic syndrome (MDS) (p = 0.011), FLT3 abnormalities (p = 0.032), CCI (p = 0.0037) and Dombret et al. score (p = 0.045) as independent prognostic parameters for survival.
|
19274612 |
2009 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
|
19276253 |
2009 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
LHGDN |
Although rare in MDS, FLT3 ITD is associated with a high probability of evolution to AML.
|
18503825 |
2008 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The fusion gene BCR-ABL in chronic myeloid leukemia (CML), FLT3/ITD in acute myeloid leukemia (AML), and RAS mutations in myelodysplastic syndromes (MDS)/myeloproliferative diseases (MPD) result in ROS production.
|
18467025 |
2008 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
LHGDN |
These results suggest that Flt3 inhibitors might exert an anti-neoplastic effect in high-risk MDS and AML through inhibition of NFkappaB.
|
18670883 |
2008 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
|
18503825 |
2008 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
FLT3 mutation and AML/ETO in a case of Myelodysplastic syndrome in transformation corroborates the two hit model of leukemogenesis.
|
17079011 |
2007 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated FLT3 protein and its phosphorylation in the plasma from 85 patients with AML, 16 patients with myelodysplastic syndrome (MDS) and 5 patients with acute lymphoblastic leukemia (ALL).
|
17156841 |
2007 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Analysis of FLT3 gene mutations in de novo myelodysplastic syndromes. FLT3 internal tandem duplication detected in a case of refractory anemia.
|
18067020 |
2007 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
All mutations were more frequent in s-AML than in MDS and all but the FLT3-TKD were more frequent in RAEB than in RA/RARS.
|
17550846 |
2007 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
FLT3 mutations seem to be a critical additional genetic event that transforms a minority of MDS patients to AML.
|
16787503 |
2006 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, FLT3 mutations were seen in three of five patients with AML following myelodysplastic syndrome (60%) and 39 of 268 (14.6%) de novo AML patients (P < 0.05).
|
17169806 |
2006 |